Teva Pharmaceuticals announced that the FDA has approved Ajovy (fremanezumab-vfrm) for the preventive treatment of episodic migraines in pediatric patients. The approval applies to children and adolescents between the ages of 6 and 17 who weigh at least 99 pounds, according to a news release issued yesterday.

Ajovy is a calcitonin gene-related peptide (CGRP) antagonist, initially approved by the FDA in 2018 for the prevention of migraines in adults. It works by targeting CGRP, a neuropeptide that plays a key role in the development of migraines. By blocking CGRP, Ajovy helps reduce the occurrence of migraine attacks. With this new approval, Ajovy becomes the first and only CGRP antagonist cleared for both episodic and pediatric migraines.

Migraine is a complex neurological disorder wit

See Full Page